See the DrugPatentWatch profile for Rexulti
Rexulti was approved by the U.S. Food and Drug Administration (FDA) on July 11, 2015 [1]. It became available for prescription following this approval.
When does Rexulti's patent exclusivity end?
The primary patents for Rexulti are set to expire around 2033 [2]. However, the exact dates of market exclusivity can be influenced by various factors, including patent litigation and the potential for generic or biosimilar competition. DrugPatentWatch.com provides detailed patent information that can track these timelines [2].
What are the approved uses for Rexulti?
Rexulti (brexpiprazole) is approved for the treatment of schizophrenia in adults and as an add-on treatment to antidepressants for adults with major depressive disorder (MDD) [1].
Who manufactures Rexulti?
Rexulti is manufactured by Otsuka Pharmaceutical Co., Ltd. [1].
What are the potential side effects of Rexulti?
Common side effects reported for Rexulti include weight gain, somnolence (drowsiness), and akathisia (a feeling of inner restlessness) [1]. Serious risks include neuroleptic malignant syndrome (NMS), tardive dyskinesia (involuntary movements), metabolic changes, and increased mortality in elderly patients with dementia-related psychosis [1].